Content deleted Content added
Citation bot (talk | contribs) Add: authors 1-1. Removed parameters. Some additions/deletions were parameter name changes. | Use this bot. Report bugs. | #UCB_CommandLine |
Added additional deployment Tags: Visual edit Mobile edit Mobile web edit |
||
Line 91:
In November 2022, Cerebras and the [[National Energy Technology Laboratory]] (NETL) saw record-breaking performance on the scientific compute workload of forming and solving field equations. Cerebras demonstrated that its CS-2 system was as much as 470 times faster than NETL's Joule Supercomputer in field equation modeling.<ref>{{Cite web |title=Cerebras and National Energy Tech Lab Set New Milestones for High-Performance, Energy-Efficient Field Equation Modeling Using Simple Python Interface |url=https://www.hpcwire.com/off-the-wire/cerebras-and-national-energy-tech-lab-set-new-milestones-for-high-performance-energy-efficient-field-equation-modeling-using-simple-python-interface/ |access-date=2022-11-18 |website=HPCwire |language=en-US}}</ref>
The 2022 Gordon Bell Special Prize Winner for HPC-Based COVID-19 Research, which honors outstanding research achievement towards the understanding of the COVID-19 pandemic through the use of high-performance computing, used Cerebras' CS-2 system to conduct this award-winning research to transform large language models to analyze COVID-19 variants. The paper was authored by a 34-person team from Argonne National Laboratory, California Institute of Technology, Harvard University, Northern Illinois University, Technical University of Munich, University of Chicago, University of Illinois Chicago, Nvidia, and Cerebras. ANL noted that using the CS-2 Wafer-Scale Engine cluster, the team was able to achieve convergence when training on the full SARS-CoV-2 genomes in less than a day.<ref>{{Cite web |last=Peckham |first=Oliver |date=2022-11-17 |title=Gordon Bell Nominee Used LLMs, HPC, Cerebras CS-2 to Predict Covid Variants |url=https://www.hpcwire.com/2022/11/17/gordon-bell-nominee-used-llms-hpc-cerebras-cs-2-to-predict-covid-variants/ |access-date=2022-11-23 |website=HPCwire |language=en-US}}</ref><ref>{{Cite web |last=Peckham |first=Oliver |date=2022-11-17 |title=Gordon Bell Special Prize Goes to LLM-Based Covid Variant Prediction |url=https://www.hpcwire.com/2022/11/17/gordon-bell-special-prize-goes-to-llm-based-covid-variant-prediction/ |access-date=2022-11-23 |website=HPCwire |language=en-US}}</ref>
[[Mayo Clinic]] announced a collaboration with Cerebra’s at the 2024 [[J.P. Morgan & Co.|J.P. Morgan Healthcare Conference]], offering details on the first foundation model it will develop with the enablement of Cerebras's generative AI computing capability. The solution will combine genomic data with de-identified data from patient records and medical evidence to explore the ability to predict a patient's response to treatments to manage disease and will initially be applied to [[rheumatoid arthritis]]. The model could serve as a prototype for similar solutions to support the diagnosis and treatment of other diseases.
== See also ==
| |||